Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.


TSXV:CZO - Post by User

Comment by prophetoffactzon Feb 11, 2024 4:41pm
83 Views
Post# 35874712

RE:RE:RE:Shareholder value???

RE:RE:RE:Shareholder value???
Tencents wrote: In addition to above we should take into consideration aezs management comments in its  financial statements which states aezs expects to make significant losses for the foreseeable future 
this probably meabb nes  the cash on hand will be eaten up by end 2025 and tax losses will not be used in the short to medium term 


If the merger was cancelled the parties could have informed us by now. We've received nothing. A delay in the deal could bring new developments as AEZS's diagnostic clinical trial was to be fully enrolled by the end of 2023. Results from the trial could be near and this could support a licensing deal. CZO's avenanthramide clinical trial could also be nearing completion of the single ascending dose portion of the trial. There is also the question of CZO's main client returing and the launch of the powder formulations. The 5X PGX scale-up was also to be commissioned in Q1 as Natex works on the 10X scale-up. There could be an update here. CZO had als designed an animal trial for the immune booster as of the day the financials were released which could help increase confidence in that program.
<< Previous
Bullboard Posts
Next >>